Tag: Medical

Weight Loss Drug Users Are Giving Up Their Vices

[ad_1]

Image: Hollie Adams (Reuters)

It’s not only food CEOs who need to worry about their bottom lines thanks to in-demand weight loss drugs like Ozempic. Big Tobacco and Alcohol have reason to fret, too.

The Best Things You Didn’t Know Your Switch Could Do

A new report from Morgan Stanley finds that people using GLP-1 drugs — among them Ozempic, Wegovy, Mounjaro, and Zepbound — reduce their consumption of tobacco and alcohol while taking the medications. GLP-1s are a class of diabetes and weight loss drugs that have recently caught fire (and blown up sales numbers) for their ability to suppress a user’s appetite.

The investment bank also surveyed about 300 GLP-1 users about their consumption habits while taking the medication. Analysts at the bank have previously cautioned that the growing use of GLP-1s will put some longterm pressure on fast food sales, as users have reported spending less money at restaurants. But their survey also finds that users are reducing their intake of tobacco and alcohol.

Could weight loss drugs help users smoke or drink less?

While 40% of survey respondents said they smoked cigarettes at least weekly before starting a GLP-1 treatment, that number fell to 24% after they started the treatment. Meanwhile, weekly e-cigarette usage dropped from 30% of respondents to 16% after they started taking a GLP-1.

Morgan Stanley found similar results when it asked respondents about their use of alcohol. About 56-62% of alcohol consumers on GLP-1s reported drinking less alcohol since starting the medications, with about 14-18% cutting their alcohol consumption entirely.

The analysts noted they were “cautious about drawing conclusions” from their survey about the impact of GLP-1 drugs on addictive behaviors. But there has been anecdotal evidence from patients and health care providers that suggests GLP-1s can help users curb their addictions to alcohol and tobacco. While research hasn’t yet proven a causal link between the two, clinical trials are currently underway to better understand the effects of GLP-1’s on alcohol and tobacco consumption.

In addition, Morgan Stanley anticipates the GLP-1 frenzy isn’t slowing anytime soon. global market for GLP-1 drugs will reach $105 billion by 2030. It also projects these drugs will be adopted by about 31.5 million people in the U.S. (or about 9% of the nation’s population) by 2035.

This article originally appeared on Quartz.

[ad_2]

Bruce Gil, Quartz

Source link

April 23, 2024
Strs Ohio Has $1.88 Million Stock Position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

[ad_1]

Strs Ohio cut its stake in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI – Free Report) by 5.7% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 26,300 shares of the biopharmaceutical company’s stock after selling 1,600 shares during the period. Strs Ohio’s holdings in Intra-Cellular Therapies were worth $1,883,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of ITCI. Lazard Asset Management LLC acquired a new position in Intra-Cellular Therapies during the 2nd quarter worth about $29,000. International Assets Investment Management LLC acquired a new position in shares of Intra-Cellular Therapies in the fourth quarter worth approximately $51,000. State of Wyoming lifted its stake in shares of Intra-Cellular Therapies by 57.9% in the second quarter. State of Wyoming now owns 851 shares of the biopharmaceutical company’s stock worth $54,000 after acquiring an additional 312 shares during the period. Neo Ivy Capital Management bought a new stake in Intra-Cellular Therapies in the third quarter valued at approximately $45,000. Finally, Coppell Advisory Solutions Corp. acquired a new stake in Intra-Cellular Therapies during the 4th quarter valued at approximately $47,000. 92.33% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $101.00 price objective on shares of Intra-Cellular Therapies in a research note on Friday, February 23rd. The Goldman Sachs Group upped their price target on shares of Intra-Cellular Therapies from $67.00 to $77.00 and gave the company a “neutral” rating in a research report on Wednesday. TD Cowen increased their price target on Intra-Cellular Therapies from $80.00 to $90.00 and gave the stock a “buy” rating in a report on Wednesday. Bank of America boosted their price objective on Intra-Cellular Therapies from $82.00 to $91.00 and gave the company a “buy” rating in a research note on Wednesday. Finally, Canaccord Genuity Group decreased their target price on Intra-Cellular Therapies from $101.00 to $100.00 and set a “buy” rating for the company in a research note on Friday, February 23rd. Two investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $86.17.

Get Our Latest Report on Intra-Cellular Therapies

Intra-Cellular Therapies Stock Performance

Shares of NASDAQ:ITCI opened at $72.37 on Friday. Intra-Cellular Therapies, Inc. has a 52-week low of $45.50 and a 52-week high of $84.89. The business’s 50 day simple moving average is $69.31 and its two-hundred day simple moving average is $64.10. The firm has a market cap of $7.01 billion, a P/E ratio of -49.57 and a beta of 1.02.

Intra-Cellular Therapies (NASDAQ:ITCI – Get Free Report) last issued its earnings results on Thursday, February 22nd. The biopharmaceutical company reported ($0.30) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.44) by $0.14. Intra-Cellular Therapies had a negative return on equity of 23.02% and a negative net margin of 30.08%. The company had revenue of $132.10 million for the quarter, compared to analyst estimates of $135.97 million. During the same period in the prior year, the firm earned ($0.45) earnings per share. Intra-Cellular Therapies’s revenue for the quarter was up 50.3% on a year-over-year basis. On average, equities analysts forecast that Intra-Cellular Therapies, Inc. will post -0.69 earnings per share for the current fiscal year.

Insider Buying and Selling at Intra-Cellular Therapies

In other news, EVP Michael Halstead sold 7,907 shares of the business’s stock in a transaction dated Monday, February 26th. The shares were sold at an average price of $69.53, for a total transaction of $549,773.71. Following the completion of the sale, the executive vice president now directly owns 29,700 shares of the company’s stock, valued at $2,065,041. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. In related news, CEO Sharon Mates sold 40,712 shares of the stock in a transaction on Thursday, March 7th. The stock was sold at an average price of $66.50, for a total value of $2,707,348.00. Following the completion of the sale, the chief executive officer now directly owns 1,050,309 shares of the company’s stock, valued at approximately $69,845,548.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Michael Halstead sold 7,907 shares of the firm’s stock in a transaction on Monday, February 26th. The shares were sold at an average price of $69.53, for a total value of $549,773.71. Following the transaction, the executive vice president now owns 29,700 shares in the company, valued at $2,065,041. The disclosure for this sale can be found here. Over the last three months, insiders have sold 168,487 shares of company stock valued at $11,364,950. Corporate insiders own 3.40% of the company’s stock.

Intra-Cellular Therapies Profile

(Free Report)

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.

Featured Stories

Want to see what other hedge funds are holding ITCI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Intra-Cellular Therapies, Inc. (NASDAQ:ITCI – Free Report).

Receive News & Ratings for Intra-Cellular Therapies Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Intra-Cellular Therapies and related companies with MarketBeat.com’s FREE daily email newsletter.

[ad_2]

ABMN Staff

Source link

April 21, 2024
Unbelievable facts

[ad_1]

The surgery is called orthognathic surgery. It’s a long haul, usually over 3 years, and…

[ad_2]

Source link

April 10, 2024
Bellecapital International Ltd. Grows Stock Holdings in Pfizer Inc. (NYSE:PFE)

[ad_1]

Bellecapital International Ltd. raised its holdings in shares of Pfizer Inc. (NYSE:PFE – Free Report) by 41.3% in the fourth quarter, Holdings Channel reports. The institutional investor owned 46,123 shares of the biopharmaceutical company’s stock after acquiring an additional 13,491 shares during the period. Bellecapital International Ltd.’s holdings in Pfizer were worth $1,328,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently modified their holdings of PFE. Moneta Group Investment Advisors LLC increased its stake in shares of Pfizer by 89,592.7% in the fourth quarter. Moneta Group Investment Advisors LLC now owns 161,143,638 shares of the biopharmaceutical company’s stock worth $8,257,000,000 after purchasing an additional 160,963,976 shares in the last quarter. Norges Bank purchased a new stake in shares of Pfizer in the fourth quarter worth $3,150,472,000. Charles Schwab Investment Management Inc. increased its stake in shares of Pfizer by 10.9% in the third quarter. Charles Schwab Investment Management Inc. now owns 95,772,746 shares of the biopharmaceutical company’s stock worth $3,161,261,000 after purchasing an additional 9,393,992 shares in the last quarter. Morgan Stanley increased its stake in shares of Pfizer by 10.3% in the fourth quarter. Morgan Stanley now owns 79,499,361 shares of the biopharmaceutical company’s stock worth $4,073,547,000 after purchasing an additional 7,419,929 shares in the last quarter. Finally, Renaissance Technologies LLC bought a new position in shares of Pfizer during the first quarter worth $311,238,000. 68.36% of the stock is owned by hedge funds and other institutional investors.

Pfizer Price Performance

Pfizer stock opened at $27.75 on Monday. The stock has a market cap of $157.14 billion, a price-to-earnings ratio of 77.08, a price-to-earnings-growth ratio of 1.24 and a beta of 0.61. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.91 and a quick ratio of 0.69. Pfizer Inc. has a 1 year low of $25.61 and a 1 year high of $42.22. The firm has a 50-day moving average of $27.44 and a two-hundred day moving average of $29.37.

Pfizer (NYSE:PFE – Get Free Report) last posted its quarterly earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 EPS for the quarter, beating the consensus estimate of ($0.19) by $0.29. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. The business had revenue of $14.25 billion during the quarter, compared to analyst estimates of $14.37 billion. During the same quarter in the previous year, the business posted $1.14 EPS. The company’s quarterly revenue was down 41.3% compared to the same quarter last year. On average, research analysts forecast that Pfizer Inc. will post 2.22 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on PFE. Guggenheim began coverage on shares of Pfizer in a report on Friday, February 23rd. They issued a “buy” rating and a $36.00 price target on the stock. UBS Group reduced their price target on shares of Pfizer from $34.00 to $27.00 and set a “neutral” rating on the stock in a report on Thursday, December 14th. TD Cowen downgraded shares of Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price target on the stock. in a report on Thursday, January 4th. Truist Financial reduced their price target on shares of Pfizer from $42.00 to $36.00 and set a “buy” rating on the stock in a report on Thursday, December 14th. Finally, Argus downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. Twelve analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $36.88.

View Our Latest Analysis on Pfizer

About Pfizer

(Free Report)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women’s health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Featured Stories

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE – Free Report).

Receive News & Ratings for Pfizer Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Pfizer and related companies with MarketBeat.com’s FREE daily email newsletter.

[ad_2]

ABMN Staff

Source link

April 1, 2024
Some cancer patients can find it hard to tell family and friends about their diagnosis: ‘You’re dealing with this all alone’

[ad_1]

Ever since Anthony Bridges found out he had prostate cancer six years ago, he hasn’t stopped talking about it. He told his Facebook friends immediately.

Now, the 68-year-old man from Georgia spends time working with others to encourage other men to talk to their doctor about getting screened.

Not everyone is as eager to share, for cultural or privacy reasons — or because they just don’t want to talk about it. Defense Secretary Lloyd Austin kept his prostate cancer quiet, including from President Joe Biden. And more recently, Kate, Princess of Wales, waited weeks before publicly disclosing her cancer.

Austin described his diagnosis as a “gut punch” and his instinct was to keep it private. In a video statement, Kate said it was a “huge shock” and that she and her husband, Prince William, had been trying to “manage this privately for the sake of our young family.”

Their reactions hardly surprised experts. Dr. Otis Brawley says he’s encountered men who don’t even want to talk about their prostate cancer with their own doctors.

Brawley, a professor of oncology and epidemiology at Johns Hopkins University, recalled a time decades ago when cancer simply wasn’t spoken of, called the ”Big C” instead.

Public conversations around prostate cancer changed, he said, when former Sen. Bob Dole announced his diagnosis and publicly spoke of erectile dysfunction, a side effect of treatment.

For breast cancer, it was first lady Betty Ford, who spoke openly about her surgery and treatment.

“That opened the floodgates. It was then OK to talk about cancer,” Brawley said.

In the U.S., death rates from cancer have been declining for decades, which is attributed to progress against lung cancer, screening and better treatments. Still, it remains the nation’s No. 2 killer, behind heart disease, and cases are increasing as the population ages and grows.

Elaine Smith, who counsels patients at City of Hope Cancer Center Atlanta, said a patient’s openness often depends on personality. Some don’t want to be identified solely as a cancer patient.

“So many of my patients say people talk to them with a different tone of voice,” Smith said. “‘They lean into me differently, they look at me with their eyes differently.’”

Sometimes people worry about how their coworkers will react when they have to miss work for appointments and treatments.

“In many cases, we may not acknowledge it, but …. that can sometimes have a role in how they are judged in their work performance,” said Dr. Bradley Carthon, of Emory University’s Winship Cancer Institute.

Patients usually share with their family, experts said, but even that can be difficult.

Kate noted it had taken time to explain “everything to George, Charlotte and Louis in a way that is appropriate for them and to reassure them that I’m going to be OK.”

“She has the added challenges of having young children,” said Dr. Christina Annunziata, a cancer doctor at the Inova Schar Cancer Institute in Fairfax, Virginia. “As hard as it is to explain to friends and family, or even coworkers. It’s even harder to explain to young children.”

The downside of keeping it private is that ”you’re dealing with this all alone,” Carthon said.

Dr. Paul Monk, who treats cancer patients at Ohio State University Wexner Medical Center, said it’s important for patients to bring along a family member or other support to appointments.

“I don’t think they hear everything I say,” he said. “And so when you bring someone else to your doctor’s visit, that’s another set of ears and I think that’s critically important.”

Bridges’ wife, Phyllis, served in that role for him when he started treatment for advanced prostate cancer in 2018. He said he had no symptoms and had only gone for a checkup at her insistence.

Bridges felt called to share his story with others, especially with Black men, and is now part of a program called Project Elevation. Working through local churches, the program’s goal is to remove some of the stigma surrounding prostate cancer and provide information about screening.

“We have to change the mindset,” said the Albany, Georgia, resident. “We have to dispel the fear.”

Subscribe to Well Adjusted, our newsletter full of simple strategies to work smarter and live better, from the Fortune Well team. Sign up for free today.

[ad_2]

Kenya Hunter, The Associated Press

Source link

March 28, 2024
Worst Side Effects Ozempic Users Don’t Want You To Know About

[ad_1]

While diarrhea is listed as a common side effect, none of the literature tells you that you will experience horrific visions of future wars, famines, and natural disasters every time you have a bowel movement—and worst of all, no one will believe you.

[ad_2]

Source link

March 27, 2024
Organs from Cannabis Consumers Don’t Pose Risks of Infection | High Times

[ad_1]

A study published in the American Journal of Transplantation recently shows that organs that come from donors with a history of recent cannabis use don’t show signs of infection or significant risk.

The study was conducted by a handful of researchers from University of California, San Francisco, University of Pennsylvania, and Temple University, and funded by National Institutes of Health, the Centers for Disease Control and Prevention (CDC), and Transplant Foundation Innovative Research Grant Program. Researchers examined information from three specific transplant centers located in Philadelphia, Pennsylvania, between transplants that were conducted by the Gift of Life Program between January 1, 2015-June 30, 2016.

According to the CDC, organ transplant patients take anti-rejection medicine that lowers their body’s immune system response, which helps their bodies accept the new organ. That same medicine can sometimes lead to mild or life-threatening infections, which can develop days, weeks, months, or even years after transplant surgery occurs.

The authors explained that cannabis leaves sometimes contain harmful bacteria or fungi, and inhaled cannabis has also been found in relation to infections in transplant patients. This study addressed the question regarding if cannabis consumer’s organs are harmful to patients on the organ receiving end. “The goal of our study is to better characterize the infection risks that marijuana use among deceased organ donors may pose to [solid organ transplants] recipients,” the authors wrote.

The authors explained the importance of their findings amidst the rising percentage of people consuming cannabis regularly. “It is likely that a growing proportion of deceased organ donors have a history of marijuana use, as well, though this metric has not been specifically reported,” authors said.

The study examined donors with cannabis use within the last 12 months prior to the study, as well as donors with no recent cannabis use history. “Despite concern that donor exposure to marijuana increases the risk of fungal infection in recipients, our study found that a donor history of marijuana use did not increase (1) the likelihood of donor culture positivity (including respiratory cultures), or (2) the risk of early recipient bacterial or fungal infection, graft failure, or death posttransplant,” the study stated. “Even when evaluating only lung recipients, there remained no association between donor marijuana use and the risk of posttransplant infection.”

The researchers explored a variety of data from the three transplant facilities, such as donors who experienced bacterial or fungal infections, or if the transplant failed and led to death in the patient. Overall, organs from consumers with recent cannabis use posed little threat to the patients. “Among donors with a history of recent marijuana use, 79 (89%) had at least 1 positive culture, compared to 264 (87%) among those with no history of marijuana use,” researchers wrote. “On donor respiratory cultures, 76 (85%) donors with a history of recent marijuana use and 250 (82%) donors with no history of recent marijuana use had bacterial or fungal growth on respiratory cultures. On both unadjusted analyses and multivariable analyses, there was no association between recent donor marijuana use and donor culture positivity.”

However, it’s important to note that the data that researchers reviewed was collected well after transplants occurred, and relied on next-of-kin to help measure a patient’s cannabis use. This was described as an “imperfect measure” of data collection.

“In conclusion, our study demonstrates that donors with a history of recent marijuana use are not more likely to have positive donor cultures, and their recipients are not more likely to develop a bacterial or fungal infection, graft failure, or death in the early posttransplant period (in the context of current management),” the study concluded. “These results suggest that organs from donors with a history of recent marijuana use do not pose significant novel infectious risks to recipients in the early posttransplant period.”

Currently, medical cannabis patients often experience discrimination when seeking out health care, but specifically encounter restrictions when it comes to organ transplants, according to a report published by the Petrie-Flom Center at Harvard Law School last October. “Many transplant centers prevent cannabis users from receiving solid organ transplantation due to concerns regarding interactions between cannabis and immunosuppressant drugs used for transplants, treatment non-adherence, fungal infections, and neuropsychiatric effects,” the report stated. As a result, medical cannabis patients are often ineligible for transplant.

The review adds that larger-scale studies are needed in order to determine if medical cannabis consumption “…should not be an absolute contraindication to solid organ transplantation.” Furthermore, some research shows evidence of medical cannabis helping to prevent transplant rejection in some patients.

Last year, another study found that cannabis use isn’t a risk for liver transplant patients. Researchers found no correlation between cannabis and non-cannabis users, stating that there was “no statistically significant associations between marijuana use with post-transplant bacterial or fungal infections, medication non-compliance, or continued substance use.”

[ad_2]

Nicole Potter

Source link

March 22, 2024
Haunting ‘Demon Faces’ Show What It’s Like to Have Rare Distorted Face Syndrome

[ad_1]

A 58-year-old man with a rare medical condition sees faces normally on screens and paper, but in person, they take on a demonic quality. The patient has a unique case of prosopometamorphopsia (PMO), a condition that causes peoples’ faces to appear distorted, reptilian, or otherwise inhuman.

The Fujifilm X100VI is the Most Fun I’ve Had With a Camera in Years

A new study published in The Lancet describes the case, which is unique in that, to the man, the faces only appear demonic when the individuals are physically present. The patient has been perceiving faces as distorted for 31 months; at first, it was distressing to him, but now, he has “become habituated to them,” the paper states.

Because faces appear ordinary to him on screens and in person, the research team had a unique opportunity to probe how the distortions manifest and create accurate visualizations of the “demonic” countenances.

“In other studies of the condition, patients with PMO are unable to assess how accurately a visualization of their distortions represents what they see because the visualization itself also depicts a face, so the patients will perceive distortions on it too,” said Antônio Mello, a researcher at Dartmouth College and lead author of the study, in a university release. “Through the process, we were able to visualize the patient’s real-time perception of the face distortions.”

For the patient, faces in person are unsettlingly distorted. Eyes are stretched and angular, nostrils flare out and lips stretch outwards to comprise the entire width of the face. Grooves appear in the forehead, and ears warp into an elvish shape, ending in sharp points. In milder cases, facial features merely droop, appear out of position, or are smaller or larger than they are in real life.

In another case, published in The Lancet in 2014, a 52-year-old woman in The Netherlands reported:

A life-long history of seeing people’s faces change into dragon-like faces and hallucinating similar faces many times a day. She could perceive and recognise actual faces, but after several minutes they turned black, grew long, pointy ears and a protruding snout, and displayed a reptiloid skin and huge eyes in bright yellow, green, blue, or red. She saw similar dragon-like faces drifting towards her many times a day from the walls, electrical sockets, or the computer screen, in both the presence and absence of face-like patterns, and at night she saw many dragon-like faces in the dark.

According to Brad Duchaine, senior author on the study and principal investigator of Dartmouth’s Social Perception Lab, people suffering from PMO are often diagnosed with other disorders, like schizophrenia, and prescribed anti-psychotics.

“It’s not uncommon for people who have PMO to not tell others about their problem with face perception because they fear others will think the distortions are a sign of a psychiatric disorder,” Duchaine said. “It’s a problem that people often don’t understand.”

The 58-year-old patient had a history of bipolar affective disorder and post-traumatic stress disorder (PTSD), the research team noted, as well as a head injury when he was 43 years old. The patient had no impairments to eyesight and a small round lesion on his left hippocampus, which the team concluded was a cyst. Other individuals suffering from an Alice in Wonderland syndrome (a catch-all term for perceptual distortions) also were reported to have brain lesions; encephalitis, migraines, and psychoactive drug use are also linked with the syndrome, though none were observed in the recent patient’s case.

To characterize the facial distortions, the researchers had the man describe perceived differences between the face of a person in the room with him and a photo of that person. Due to his PMO, the in-person face was distorted, and the on-screen face looked like an ordinary face.

PMO can last just days for some, and years for others. Only 75 case reports of PMO have been published, according to the researchers. It’s certainly one of the rare—and more disturbing—perceptual disorders, but knowing how it manifests means that fewer patients will be misdiagnosed in the future.

More: Vital Clues to Chronic Fatigue Syndrome Found in Major New Study

[ad_2]

Isaac Schultz

Source link

March 21, 2024
Study Finds No Strong Evidence for Benefits of Wim Hof Method

[ad_1]

New research this week seems to throw cold water on the Wim Hof method, an endurance training technique that intentionally exposes people to frigid temperatures. The study, a review of the scientific literature, did find some evidence that the method could have anti-inflammatory properties, but did not find strong data supporting any other supposed benefits, such as better exercise performance.

Kara Swisher on All the Nonsense in the Tech Industry

The method is named after Wim Hof, a Dutch athlete and motivational speaker who has accomplished some remarkable feats in extreme conditions. Hof, nicknamed the Iceman, has reportedly run a half marathon (13.1 miles) above the Arctic Circle barefoot, climbed Mount Kilimanjaro in just shorts, and withstood being immersed in ice water for nearly two hours. Critics have scrutinized some of his purported accomplishments, but he is still officially recognized as having earned 18 Guinness World Records.

Hof has long credited his endurance and general well-being to the namesake method, which combines being submerged in cold water with specific breathing and meditation techniques. And there have been some empirical attempts to validate his claims. The authors of this new research, published Wednesday in the journal PLOS-One, reviewed data from nine such studies, including eight trials. Overall, the verdict was decidedly indecisive.

The review found that the method might reduce inflammation in both healthy and unhealthy individuals, for instance, possibly by increasing the body’s levels of adrenaline. But the research looking at whether the method actually improved someone’s exercise performance “showed mixed findings.” And even the positive results should be taken with a grain of salt, the authors noted, since most of the studies were judged to have a high risk of bias and were generally considered poor quality for various reasons, such as a small sample size and an inability to blind participants to whether they were using the method or not (without good blinding, it can be easy for things like the placebo effect to affect results).

Despite these important caveats, the authors tried to paint their results in the best light possible, stating that the Wim Hof method “may produce promising immunomodulatory effects but more research of higher quality is needed to substantiate this finding.” But outside experts have been more openly critical about the implications of this study.

“As revealed by the review, the science is too weak/biased to conclude what the Wim Hof method achieves,” Mike Tipton, a professor of human and applied physiology at the University of Portsmouth in the United Kingdom and cold water survival expert, told CNN.

The method might not come without its risks either. There have been numerous deaths possibly tied to the practice. In December 2022, the family of California teenager Madelyn Rose Metzger sued Wim Hof, alleging that his breathing techniques contributed to 17-year-old Madelyn’s accidental drowning death earlier that summer (the case appears to be ongoing). And people with certain health conditions such as asthma, high blood pressure and a history of seizures are not advised to submerge themselves in cold water, according to Tipton.

A spokesperson for Wim Hof and his organization told CNN that it recognizes the need for better quality research to validate the claimed benefits of the method, and that it is committed to collaborating ”with the scientific community to conduct larger, more inclusive studies that address these concerns.”

[ad_2]

Ed Cara

Source link

March 15, 2024
German Man Receives 217 Covid Vaccines

[ad_1]

A German man who voluntarily received 217 Covid 19 vaccines in the span of 29 months has experienced no negative health effects, according to researchers, although doctors still do not endorse hyper-vaccination to boost immunity. What do you think?

“Looks like someone has Pfizer stock.”

Sandra Bodnar, General Fireproofer

Marianne Williamson Successfully Primaries Biden In All 63 Counties Of Astral Plane

“Uh oh, now he’s got to get 217 boosters!”

Doug Rinaldo, Trivia Aggregator

“Jeez, I can’t imagine getting more than 150.”

Cyrus Sprecher, unemployed

[ad_2]

Source link

March 8, 2024
Introducing 323MD: Your Ultimate Medical Tablet

[ad_1]

Revolutionizing Point-of-Care Technology

In today’s fast-paced healthcare environment, efficiency and accessibility are paramount. That’s why DT Research has unveiled the 323MD medical tablet, a game-changer in point-of-care technology. This purpose-built tablet is meticulously engineered to deliver seamless care across a myriad of healthcare settings, from bustling hospitals to remote field clinics.

Versatility Meets Durability

The 323MD medical tablet is a true powerhouse, boasting a 13-inch sunlight-readable touchscreen and high-performance Intel® Core™ processors. This sleek and lightweight device is not only highly versatile but also incredibly durable, with an IP65 rating and MIL-STD-810H/461G certification. Whether you’re in the emergency room or out in the field, the 323MD is designed to withstand the rigors of healthcare environments.

Empowering Healthcare Professionals

Gone are the days of being tethered to a stationary workstation. With the 323MD medical tablet, healthcare professionals have the freedom to move seamlessly from one patient to the next. The tablet’s detachable keyboard allows for effortless transitions between stationary and mobile use, while built-in Wi-Fi, barcode scanners, RFID, GNSS data capture, and front/back cameras enhance workflow efficiency. This means more time spent caring for patients and less time navigating cumbersome technology.

Elevating Patient Care

At the heart of the 323MD medical tablet is a commitment to patient-centric care. The tablet’s Windows® 10/11 IoT Enterprise operating system ensures compatibility with existing healthcare systems, while its high-brightness display is ideal for detailed imaging, such as X-rays. With hot-swappable batteries and a fanless design, healthcare professionals can rely on the 323MD to perform reliably in even the most challenging environments. Plus, with antimicrobial enclosures and certification to meet ANSI/AAMI ES60601-1 standards, you can trust that patient safety is always the top priority.

Conclusion

In conclusion, the 323MD medical tablet is poised to revolutionize the way healthcare is delivered. Its versatility, durability, and commitment to patient care make it the ultimate point-of-care solution for healthcare professionals everywhere. Whether you’re in a bustling hospital or a remote field clinic, the 323MD is your trusted companion in providing top-notch care to those who need it most.

Like this:

Like Loading…

[ad_2]

Al Hilal

Source link

March 6, 2024
Your Screen Protector Is Not All It’s Cracked Up to Be

[ad_1]

When you’re buying a new smartphone, salesmen love pestering you to buy some increased protection — insurance, a case, and, obviously, a screen protector. The screen protector has long been hailed as a necessity, costing anywhere from $10 to $60. These little slips of plastic and glass have ballooned to a $50 billion industry, but there’s a dirty secret underneath it all. Your screen protector may not be essential anymore.

Is USB-C Finally Coming To iPhone?

You wouldn’t be crazy for wanting to protect your screen. Cracking your screen is the number one way to break your phone, followed by water damage and battery issues. However, the glass in your phone has gotten significantly stronger in the last five years. Some experts say you might be able to skip the screen protector, and even warn about some relatively unknown downsides that salespeople aren’t telling you.

“It’s really not particularly useful,” said Raymond Soneira, CEO of DisplayMate Technologies, about screen protectors in an interview with Gizmodo. Soneira’s company researches how to optimize your phone’s display. He doesn’t use a screen protector, just a phone case, but caveats this by noting he is very careful with his phone and rarely ever drops it.

DisplayMate found that screen protectors make your phone more reflective. This reduces the quality of your display and requires you to increase your phone’s brightness to match the same quality. Over time, he says this will wear down your phone’s battery, and give you a shorter daily battery life.

However, the phone community is mixed on this screen protector issue. iFixit Repairability Engineer, Carsten Fraunheim notes that screen protectors can be useful against scratches, micro-abrasions, and just give you peace of mind. He calls them a “no-brainer” but admits they’re less essential than they used to be.

“As smartphone glass tech becomes more and more shatter resistant, screen protectors will lose their ‘drop protection’ selling feature,” Fraunheim said in an email.

Even the liquid screen protectors have their issues.

“Liquid wipe-on screen protectors are snake oil,” said iFixit CEO Kyle Wiens in an email. He says that this variety of protection actually compromises the structure of your screen, though he had no comment on panel-style protectors.

Trey Barnett, a computer technician at a Manhattan uBreakiFix, has seen a lot of cracked screens in the 14 years he’s been repairing phones. However, he sees fewer iPhones with broken screens than he used to.

“I would say that screens have gotten a bit stronger, but, you know, it hasn’t stopped people from breaking them altogether.”

There is an obvious argument in favor of screen protectors: they cost less than replacing your phone screen. While that’s true, the chances of having to repair your screen are far lower than they used to be. The multi-billion dollar screen protector industry would like to keep that on the down low.

Origins of The Screen Protector

In 2021, Apple’s iPhones started using Ceramic Shield, a new material that claims to be tougher than any previous smartphone glass. It comes from Corning, a glass company that Steve Jobs commissioned to produce the first screen for the iPhone in 2007.

Jobs famously gave Corning a 6-month deadline to produce the iPhone’s screen, which was originally planned to be plastic. Corning got it done, creating an especially strong, thin material called Gorilla Glass. This material would be used in the first decade of iPhones and is still used in most Samsung phones.

Gorilla Glass is stronger than most glass, but it wasn’t great at first. Screen protectors for phones almost immediately popped up, as consumers raced to wrap their phones in protective materials.

Apple forums in 2008 were full of people discussing early screen protectors. The first iPhone adopters quickly scratched their Gorilla Glass displays. Some users found these early screen protectors were so bad they messed with the iPhone’s touch screen. Screen protectors have gotten much better, but so have screens themselves.

Ceramic Shield was a major leap forward for screen technology. The materials used in Ceramic Shield are much different from typical smartphone glass. Corning describes it as somewhere in between ceramics and glass, and Apple says it’s four times stronger than Gorilla Glass when it comes to drops.

However, these major improvements have flown under the radar. That may have something to do with the growth of the screen protector industry. By 2030, the industry is expected to grow to roughly $85 billion, according to Grand View Research.

Why Screen Protectors Persist

Anyone who has cracked their phone screen will tell you how painful that experience is. Even though phone screens have gotten much better, the replacement process is scarring enough to make anyone just buy the dang screen protector.

It’s totally understandable why you might put your phone in a screen protector still. It is a large investment, but there’s more and more evidence that screens are getting better. A good phone case alone may be sufficient.

So at what point do we ditch the screen protectors? These flimsy films could be degrading the quality of that very expensive screen in your pocket, and they are potentially running through your battery. Screen protectors are slowly becoming a thing of the past.

[ad_2]

Maxwell Zeff

Source link

March 4, 2024
Deutsche Bank AG Buys 7,565 Shares of Beyond Air, Inc. (NASDAQ:XAIR)

[ad_1]

Deutsche Bank AG boosted its stake in shares of Beyond Air, Inc. (NASDAQ:XAIR – Free Report) by 1.9% during the third quarter, Holdings Channel.com reports. The firm owned 407,565 shares of the company’s stock after purchasing an additional 7,565 shares during the quarter. Deutsche Bank AG’s holdings in Beyond Air were worth $941,000 as of its most recent SEC filing.

Other institutional investors also recently added to or reduced their stakes in the company. BlackRock Inc. raised its stake in Beyond Air by 497.6% in the second quarter. BlackRock Inc. now owns 1,728,410 shares of the company’s stock valued at $7,363,000 after buying an additional 1,439,168 shares during the last quarter. State Street Corp raised its stake in Beyond Air by 259.5% in the second quarter. State Street Corp now owns 368,154 shares of the company’s stock valued at $1,568,000 after buying an additional 265,747 shares during the last quarter. Geode Capital Management LLC raised its stake in Beyond Air by 93.1% in the second quarter. Geode Capital Management LLC now owns 501,409 shares of the company’s stock valued at $2,136,000 after buying an additional 241,688 shares during the last quarter. Northern Trust Corp raised its stake in Beyond Air by 202.3% in the second quarter. Northern Trust Corp now owns 250,245 shares of the company’s stock valued at $1,066,000 after buying an additional 167,458 shares during the last quarter. Finally, Jane Street Group LLC raised its stake in Beyond Air by 1,353.9% in the first quarter. Jane Street Group LLC now owns 132,915 shares of the company’s stock valued at $897,000 after buying an additional 143,515 shares during the last quarter. Institutional investors own 30.60% of the company’s stock.

Analyst Ratings Changes

Separately, Truist Financial reduced their price objective on Beyond Air from $14.00 to $10.00 and set a “buy” rating for the company in a research note on Tuesday, November 14th.

Get Our Latest Stock Report on XAIR

Beyond Air Trading Down 3.4 %

Shares of NASDAQ:XAIR opened at $1.98 on Friday. The business has a 50-day moving average price of $1.78 and a 200-day moving average price of $2.10. The company has a quick ratio of 3.26, a current ratio of 3.39 and a debt-to-equity ratio of 0.61. The stock has a market cap of $71.36 million, a price-to-earnings ratio of -0.93 and a beta of -0.23. Beyond Air, Inc. has a 52-week low of $1.17 and a 52-week high of $7.16.

Beyond Air (NASDAQ:XAIR – Get Free Report) last announced its quarterly earnings results on Monday, February 12th. The company reported ($0.50) earnings per share for the quarter, beating the consensus estimate of ($0.61) by $0.11. The company had revenue of $0.39 million for the quarter, compared to analysts’ expectations of $0.49 million. During the same quarter in the prior year, the business posted ($0.43) earnings per share. Equities analysts predict that Beyond Air, Inc. will post -1.93 EPS for the current year.

Insider Buying and Selling at Beyond Air

In other Beyond Air news, CEO Steven A. Lisi acquired 77,775 shares of the company’s stock in a transaction on Monday, December 18th. The shares were bought at an average cost of $1.63 per share, with a total value of $126,773.25. Following the completion of the acquisition, the chief executive officer now owns 1,536,471 shares in the company, valued at $2,504,447.73. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, Director Robert Carey purchased 1,200,000 shares of the stock in a transaction dated Monday, December 18th. The shares were purchased at an average cost of $1.64 per share, with a total value of $1,968,000.00. Following the completion of the purchase, the director now directly owns 2,374,454 shares of the company’s stock, valued at approximately $3,894,104.56. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO Steven A. Lisi acquired 77,775 shares of the stock in a transaction on Monday, December 18th. The shares were bought at an average cost of $1.63 per share, for a total transaction of $126,773.25. Following the purchase, the chief executive officer now directly owns 1,536,471 shares of the company’s stock, valued at approximately $2,504,447.73. The disclosure for this purchase can be found here. 19.00% of the stock is owned by corporate insiders.

Beyond Air Profile

(Free Report)

Beyond Air, Inc operates as a commercial-stage medical device and biopharmaceutical company in the United States. The company engages in the development of LungFit platform, a nitric oxide generator and delivery system. It offers LungFit PH for the treatment of persistent pulmonary hypertension of the newborn.

Recommended Stories

Want to see what other hedge funds are holding XAIR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Beyond Air, Inc. (NASDAQ:XAIR – Free Report).

Receive News & Ratings for Beyond Air Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Beyond Air and related companies with MarketBeat.com’s FREE daily email newsletter.

[ad_2]

ABMN Staff

Source link

March 2, 2024
DaVita Inc. (NYSE:DVA) Shares Acquired by DekaBank Deutsche Girozentrale

[ad_1]

DekaBank Deutsche Girozentrale boosted its position in DaVita Inc. (NYSE:DVA – Free Report) by 19.1% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 9,130 shares of the company’s stock after acquiring an additional 1,463 shares during the quarter. DekaBank Deutsche Girozentrale’s holdings in DaVita were worth $877,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. Resources Management Corp CT ADV raised its holdings in DaVita by 5,900.0% in the second quarter. Resources Management Corp CT ADV now owns 300 shares of the company’s stock valued at $30,000 after acquiring an additional 295 shares in the last quarter. Harbor Investment Advisory LLC acquired a new stake in DaVita in the third quarter valued at approximately $34,000. Parkside Financial Bank & Trust raised its holdings in DaVita by 88.6% in the first quarter. Parkside Financial Bank & Trust now owns 313 shares of the company’s stock valued at $35,000 after acquiring an additional 147 shares in the last quarter. Penserra Capital Management LLC acquired a new stake in DaVita in the second quarter valued at approximately $36,000. Finally, FinTrust Capital Advisors LLC raised its holdings in DaVita by 242.3% in the third quarter. FinTrust Capital Advisors LLC now owns 712 shares of the company’s stock valued at $67,000 after acquiring an additional 504 shares in the last quarter. Institutional investors and hedge funds own 84.69% of the company’s stock.

Insider Buying and Selling

In related news, insider James O. Hearty sold 26,164 shares of the stock in a transaction on Friday, February 16th. The stock was sold at an average price of $119.64, for a total transaction of $3,130,260.96. Following the completion of the sale, the insider now directly owns 20,264 shares of the company’s stock, valued at $2,424,384.96. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In related news, insider Kathleen Alyce Waters sold 11,285 shares of the stock in a transaction on Wednesday, February 21st. The stock was sold at an average price of $120.73, for a total transaction of $1,362,438.05. Following the completion of the sale, the insider now directly owns 81,297 shares of the company’s stock, valued at $9,814,986.81. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider James O. Hearty sold 26,164 shares of the stock in a transaction on Friday, February 16th. The stock was sold at an average price of $119.64, for a total value of $3,130,260.96. Following the sale, the insider now directly owns 20,264 shares of the company’s stock, valued at $2,424,384.96. The disclosure for this sale can be found here. Insiders sold a total of 66,937 shares of company stock valued at $8,025,656 over the last three months. 1.40% of the stock is currently owned by company insiders.

DaVita Stock Performance

Shares of DVA opened at $125.25 on Friday. The company has a current ratio of 1.19, a quick ratio of 1.13 and a debt-to-equity ratio of 6.65. The firm has a market cap of $10.98 billion, a PE ratio of 16.93, a price-to-earnings-growth ratio of 1.10 and a beta of 1.00. The company’s 50 day simple moving average is $109.82 and its 200-day simple moving average is $100.07. DaVita Inc. has a 12-month low of $71.51 and a 12-month high of $128.28.

DaVita (NYSE:DVA – Get Free Report) last announced its earnings results on Tuesday, February 13th. The company reported $1.87 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.53 by $0.34. The business had revenue of $3.15 billion for the quarter, compared to analyst estimates of $3.01 billion. DaVita had a net margin of 5.70% and a return on equity of 64.42%. The company’s revenue for the quarter was up 7.8% compared to the same quarter last year. During the same period last year, the firm posted $1.11 earnings per share. As a group, equities analysts predict that DaVita Inc. will post 9.23 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have commented on the stock. UBS Group increased their price target on shares of DaVita from $113.00 to $134.00 and gave the company a “buy” rating in a research note on Wednesday, February 14th. Truist Financial increased their price target on shares of DaVita from $130.00 to $135.00 and gave the company a “hold” rating in a research note on Tuesday. StockNews.com lowered shares of DaVita from a “strong-buy” rating to a “buy” rating in a research note on Tuesday. Finally, TheStreet upgraded shares of DaVita from a “c+” rating to a “b-” rating in a research note on Wednesday, February 7th. Two analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat, DaVita presently has a consensus rating of “Moderate Buy” and an average price target of $115.60.

Check Out Our Latest Stock Analysis on DVA

DaVita Profile

(Free Report)

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.

See Also

Want to see what other hedge funds are holding DVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DaVita Inc. (NYSE:DVA – Free Report).

Receive News & Ratings for DaVita Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for DaVita and related companies with MarketBeat.com’s FREE daily email newsletter.

[ad_2]

ABMN Staff

Source link

February 24, 2024
Elon Musk Says Neuralink’s First Patient Can Move a Computer Mouse With Their Thoughts

[ad_1]

The first human implanted with a Neuralink brain chip can control a computer mouse with their thoughts, Elon Musk claimed in an X Spaces event Monday. The anonymous patient has recovered fully, according to Musk, after having a Neuralink chip implanted into their brain just a few weeks ago.

Did Elon Musk Regret Buying Twitter? | Walter Isaacson Interview

“Progress is good, patient seems to have made a full recovery … and is able to control the mouse, move the mouse around the screen just by thinking,” said Musk in a conversation on X Monday night.

Neuralink is working with the patient to get as many “button presses” as possible, purely by thinking, according to Musk. These include the patient moving a mouse around, clicking, and dragging a cursor solely with their brain. There is no evidence for these claims besides what Musk is announcing in brief snippets on X, so these claims should be taken with a grain of salt. However, if true, Neuralink’s advancements would be a major step forward for technology.

In late January, Musk announced that the first human patient had received a Nueralink implant via a tweet on X. The experimental surgery installs a microchip into the top layer of a person’s skull. Musk revealed little else about the identity of the initial patient.

Neuralink’s first product is called “Telepathy,” according to Musk, and it’s specifically designed for people who have lost the use of their limbs. The cursor movement described by Musk appears to be the very first progress on Neuralink’s Telepathy.

“Imagine if Stephen Hawking could communicate faster than a speed typist or auctioneer,” said Musk in a tweet. “That is the goal.”

Musk was criticized last week by The Hastings Center for his limited “two-sentence report” on a human test subject. Researchers noted that novel human research should not occur behind closed doors, and suggested Neuralink has failed to meet basic ethical standards.

“Opening up the brain of a living human being to insert a device, particularly someone with serious medical problems, deserves more than a two-sentence report on what is, in effect, a proprietary social media platform not distinguished for its reliability where facts are concerned,” the Center said.

The Hastings Center noted that Neuralink has not publicly shared what it plans to do if things go wrong, nor has the company shared the findings of its animal research that justified this experiment in the first place.

Despite the novelty of this human experiment from Musk and Neuralink, we still don’t know much. The company continues to only share bits of information through Musk’s X account, which is highly unusual for the scientific community but is par for the course from Musk.

[ad_2]

Maxwell Zeff

Source link

February 20, 2024
Huntington National Bank Cuts Stock Position in Bio-Rad Laboratories, Inc. (NYSE:BIO)

[ad_1]

Huntington National Bank reduced its stake in Bio-Rad Laboratories, Inc. (NYSE:BIO – Free Report) by 33.8% during the third quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 98 shares of the medical research company’s stock after selling 50 shares during the quarter. Huntington National Bank’s holdings in Bio-Rad Laboratories were worth $35,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of BIO. Massachusetts Financial Services Co. MA bought a new position in Bio-Rad Laboratories in the 3rd quarter worth $116,036,000. Parnassus Investments LLC bought a new position in Bio-Rad Laboratories in the 3rd quarter worth $79,143,000. Norges Bank bought a new position in Bio-Rad Laboratories in the 4th quarter worth $91,443,000. Artisan Partners Limited Partnership bought a new position in Bio-Rad Laboratories in the 2nd quarter worth $43,064,000. Finally, Hound Partners LLC raised its holdings in Bio-Rad Laboratories by 81.1% in the 2nd quarter. Hound Partners LLC now owns 216,546 shares of the medical research company’s stock worth $82,097,000 after purchasing an additional 96,970 shares during the period. 63.98% of the stock is owned by institutional investors.

Bio-Rad Laboratories Trading Up 0.3 %

Shares of BIO stock opened at $326.31 on Tuesday. Bio-Rad Laboratories, Inc. has a 52-week low of $261.59 and a 52-week high of $509.62. The company has a debt-to-equity ratio of 0.14, a quick ratio of 4.25 and a current ratio of 5.64. The firm has a market capitalization of $9.51 billion, a PE ratio of -55.78 and a beta of 0.89. The stock has a fifty day simple moving average of $317.31 and a two-hundred day simple moving average of $336.92.

Insider Activity

In other news, EVP Dara Wright sold 1,200 shares of the firm’s stock in a transaction dated Tuesday, December 12th. The stock was sold at an average price of $299.16, for a total transaction of $358,992.00. Following the completion of the transaction, the executive vice president now owns 1,499 shares in the company, valued at $448,440.84. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. In other news, EVP Michael Crowley sold 642 shares of the firm’s stock in a transaction dated Tuesday, November 28th. The stock was sold at an average price of $305.10, for a total transaction of $195,874.20. Following the completion of the transaction, the executive vice president now owns 6,942 shares in the company, valued at $2,118,004.20. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Dara Wright sold 1,200 shares of the firm’s stock in a transaction dated Tuesday, December 12th. The shares were sold at an average price of $299.16, for a total value of $358,992.00. Following the transaction, the executive vice president now owns 1,499 shares of the company’s stock, valued at approximately $448,440.84. The disclosure for this sale can be found here. Company insiders own 17.06% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on BIO. UBS Group began coverage on Bio-Rad Laboratories in a research note on Thursday, December 7th. They issued a “buy” rating and a $395.00 price target for the company. StockNews.com lowered Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a research note on Monday, October 30th. One analyst has rated the stock with a hold rating and four have given a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $498.50.

View Our Latest Stock Report on Bio-Rad Laboratories

About Bio-Rad Laboratories

(Free Report)

Bio-Rad Laboratories, Inc manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company operates through Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes.

Recommended Stories

Want to see what other hedge funds are holding BIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bio-Rad Laboratories, Inc. (NYSE:BIO – Free Report).

Receive News & Ratings for Bio-Rad Laboratories Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Bio-Rad Laboratories and related companies with MarketBeat.com’s FREE daily email newsletter.

[ad_2]

ABMN Staff

Source link

February 13, 2024
Q1 2024 EPS Estimates for Tenaya Therapeutics, Inc. Boosted by Analyst (NASDAQ:TNYA)

[ad_1]

Tenaya Therapeutics, Inc. (NASDAQ:TNYA – Free Report) – Investment analysts at Leerink Partnrs lifted their Q1 2024 earnings per share estimates for shares of Tenaya Therapeutics in a research report issued on Thursday, February 8th. Leerink Partnrs analyst M. Foroohar now expects that the company will earn ($0.47) per share for the quarter, up from their previous estimate of ($0.53). Leerink Partnrs has a “Outperform” rating on the stock. The consensus estimate for Tenaya Therapeutics’ current full-year earnings is ($1.69) per share. Leerink Partnrs also issued estimates for Tenaya Therapeutics’ Q3 2024 earnings at ($0.47) EPS, FY2024 earnings at ($1.99) EPS and FY2025 earnings at ($1.99) EPS.

Separately, SVB Leerink initiated coverage on shares of Tenaya Therapeutics in a research note on Thursday, November 30th. They issued an “outperform” rating and a $7.00 price target on the stock. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has an average rating of “Buy” and an average target price of $15.80.

Check Out Our Latest Stock Analysis on TNYA

Tenaya Therapeutics Price Performance

Shares of NASDAQ TNYA opened at $5.68 on Monday. Tenaya Therapeutics has a 1 year low of $1.66 and a 1 year high of $8.09. The company has a market capitalization of $386.86 million, a price-to-earnings ratio of -3.02 and a beta of 2.50. The business has a 50-day moving average of $3.30 and a two-hundred day moving average of $3.05.

Hedge Funds Weigh In On Tenaya Therapeutics

A number of institutional investors have recently modified their holdings of TNYA. Bailard Inc. acquired a new stake in Tenaya Therapeutics during the 4th quarter worth $107,000. Cornercap Investment Counsel Inc. boosted its stake in shares of Tenaya Therapeutics by 136.2% during the fourth quarter. Cornercap Investment Counsel Inc. now owns 81,255 shares of the company’s stock worth $263,000 after buying an additional 46,847 shares during the period. Redwood Wealth Management Group LLC grew its holdings in shares of Tenaya Therapeutics by 38.0% during the fourth quarter. Redwood Wealth Management Group LLC now owns 16,350 shares of the company’s stock worth $53,000 after buying an additional 4,500 shares during the last quarter. SG Americas Securities LLC increased its position in Tenaya Therapeutics by 20.0% in the 4th quarter. SG Americas Securities LLC now owns 25,337 shares of the company’s stock valued at $82,000 after acquiring an additional 4,224 shares during the period. Finally, Vanguard Group Inc. raised its stake in Tenaya Therapeutics by 8.4% during the 3rd quarter. Vanguard Group Inc. now owns 2,167,868 shares of the company’s stock valued at $5,528,000 after acquiring an additional 168,489 shares during the last quarter. 70.22% of the stock is owned by institutional investors and hedge funds.

About Tenaya Therapeutics

(Get Free Report)

Tenaya Therapeutics, Inc, a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through cellular regeneration, gene therapy, and precision medicine platforms. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy; TN-301, a small molecule for heart failure with preserved ejection fraction; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy.

Read More

Receive News & Ratings for Tenaya Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Tenaya Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.

[ad_2]

ABMN Staff

Source link

February 11, 2024
Atria Wealth Solutions Inc. Has $2.31 Million Position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

[ad_1]

Atria Wealth Solutions Inc. raised its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH – Free Report) by 5.9% during the 3rd quarter, according to its most recent filing with the SEC. The institutional investor owned 20,566 shares of the medical equipment provider’s stock after acquiring an additional 1,144 shares during the period. Atria Wealth Solutions Inc.’s holdings in Zimmer Biomet were worth $2,312,000 as of its most recent filing with the SEC.

Other institutional investors have also recently bought and sold shares of the company. Brown Brothers Harriman & Co. increased its stake in shares of Zimmer Biomet by 4.0% in the second quarter. Brown Brothers Harriman & Co. now owns 2,063 shares of the medical equipment provider’s stock valued at $300,000 after buying an additional 80 shares during the period. Private Trust Co. NA increased its stake in shares of Zimmer Biomet by 8.1% in the second quarter. Private Trust Co. NA now owns 1,105 shares of the medical equipment provider’s stock valued at $161,000 after buying an additional 83 shares during the period. Glenview Trust Co increased its stake in shares of Zimmer Biomet by 1.5% in the second quarter. Glenview Trust Co now owns 5,564 shares of the medical equipment provider’s stock valued at $810,000 after buying an additional 84 shares during the period. Bradley Foster & Sargent Inc. CT increased its stake in shares of Zimmer Biomet by 1.3% in the fourth quarter. Bradley Foster & Sargent Inc. CT now owns 6,452 shares of the medical equipment provider’s stock valued at $823,000 after buying an additional 85 shares during the period. Finally, Parallel Advisors LLC increased its stake in shares of Zimmer Biomet by 5.7% in the second quarter. Parallel Advisors LLC now owns 1,583 shares of the medical equipment provider’s stock valued at $231,000 after buying an additional 85 shares during the period. Institutional investors own 87.48% of the company’s stock.

Zimmer Biomet Stock Down 0.2 %

ZBH stock opened at $122.80 on Friday. Zimmer Biomet Holdings, Inc. has a twelve month low of $102.00 and a twelve month high of $149.25. The company has a quick ratio of 0.99, a current ratio of 1.61 and a debt-to-equity ratio of 0.39. The stock’s 50 day moving average is $121.39 and its 200-day moving average is $117.68. The firm has a market capitalization of $25.66 billion, a PE ratio of 25.11, a P/E/G ratio of 2.24 and a beta of 1.03.

Zimmer Biomet (NYSE:ZBH – Get Free Report) last posted its earnings results on Thursday, February 8th. The medical equipment provider reported $2.20 earnings per share for the quarter, beating analysts’ consensus estimates of $2.15 by $0.05. Zimmer Biomet had a return on equity of 12.79% and a net margin of 13.85%. The company had revenue of $1.94 billion for the quarter, compared to analyst estimates of $1.93 billion. During the same quarter last year, the company earned $1.88 earnings per share. The company’s revenue for the quarter was up 6.3% on a year-over-year basis. Sell-side analysts expect that Zimmer Biomet Holdings, Inc. will post 8.03 EPS for the current fiscal year.

Zimmer Biomet Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Wednesday, January 31st. Stockholders of record on Wednesday, December 27th were issued a $0.24 dividend. The ex-dividend date of this dividend was Tuesday, December 26th. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.78%. Zimmer Biomet’s dividend payout ratio is presently 19.63%.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on ZBH. Royal Bank of Canada reissued an “outperform” rating and issued a $140.00 price target on shares of Zimmer Biomet in a research note on Friday. JPMorgan Chase & Co. raised their target price on Zimmer Biomet from $115.00 to $125.00 and gave the stock a “neutral” rating in a research note on Friday. Evercore ISI cut Zimmer Biomet from an “outperform” rating to an “inline” rating and decreased their target price for the stock from $135.00 to $125.00 in a research note on Thursday, January 4th. Truist Financial raised their target price on Zimmer Biomet from $133.00 to $135.00 and gave the stock a “hold” rating in a research note on Friday. Finally, TheStreet raised Zimmer Biomet from a “c” rating to a “b-” rating in a research note on Thursday. Two analysts have rated the stock with a sell rating, eight have given a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Zimmer Biomet currently has a consensus rating of “Hold” and a consensus target price of $138.11.

Get Our Latest Analysis on ZBH

Zimmer Biomet Company Profile

(Free Report)

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company designs, manufactures, and markets orthopaedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.

Featured Articles

Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings, Inc. (NYSE:ZBH – Free Report).

Receive News & Ratings for Zimmer Biomet Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Zimmer Biomet and related companies with MarketBeat.com’s FREE daily email newsletter.

[ad_2]

ABMN Staff

Source link

February 10, 2024
Research Indicates Viagra Might Help Combat Alzheimer’s

[ad_1]

New research from scientists in the U.K. indicates that older men taking Viagra are 18% less likely to develop Alzheimer’s disease, with the researchers speculating that because the medication relaxes blood vessels, it could be improving blood flow in the brain as well as other areas of the body. What do you think?

“I’ll do anything to make sure my erections don’t get Alzheimer’s.”

Douglas Leith, Anchovy Salter

Penis Fact: Did You Know?

“I knew my natural gift of maintaining solid, long-lasting erections would one day come back to haunt me.”

Rahul Dorsey, Infant Counselor

“Good. What a tragedy it would be to become rock hard but fail to remember what a boner does.”

Ivan Israni, unemployed

[ad_2]

Source link

February 9, 2024
King Charles Diagnosed With Cancer

[ad_1]

Following a procedure to reduce an enlarged prostate, King Charles III, 75, was diagnosed with “a form of cancer” and is stepping down from public duties while he undergoes treatment. What do you think?

“I’m shocked. He’s always been the picture of health and vigor.”

Andrea Byrd, Shoe Rehabilitator

Florida Names Penis As Official State Genital

“Has his next of kin been gleefully notified?”

Marco Sharp, Yam Salesman

“Can I wear his crown while he’s sick?”

Bryson Finnegan, Dictionary Auditor

[ad_2]

Source link

February 6, 2024